Candriam S.C.A. Purchases 194,081 Shares of Bruker Corporation $BRKR

Key Points

• Candriam S.C.A. significantly increased its holdings in Bruker Corporation by buying 194,081 shares, resulting in a total ownership of 379,027 shares, valued at approximately $15.8 million.
• Bruker Corporation reported earnings of $0.32 per share for the last quarter, falling short of analysts' expectations, and set its FY 2025 EPS guidance between $1.950 to $2.050.
• Bruker has declared a quarterly dividend of $0.05 per share, with an ex-dividend date on September 23rd, representing an annual yield of 0.6%.

Candriam S.C.A. raised its position in Bruker Corporation (NASDAQ:BRKR - Free Report) by 104.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 379,027 shares of the medical research company's stock after buying an additional 194,081 shares during the quarter. Candriam S.C.A. owned about 0.25% of Bruker worth $15,821,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Pinnacle Bancorp Inc. bought a new stake in shares of Bruker in the first quarter valued at $29,000. Allworth Financial LP raised its stake in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock valued at $30,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in shares of Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after purchasing an additional 745 shares during the period. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Bruker during the 1st quarter valued at $42,000. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of Bruker by 274.9% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after purchasing an additional 800 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the company's stock in a transaction on Friday, June 6th. The stock was acquired at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the acquisition, the chief executive officer owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This represents a 0.01% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 27.30% of the company's stock.

Bruker Price Performance

BRKR opened at $33.73 on Thursday. The stock has a 50-day moving average price of $38.66 and a 200-day moving average price of $41.35. Bruker Corporation has a 12-month low of $30.00 and a 12-month high of $72.94. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $5.12 billion, a P/E ratio of 64.87, a PEG ratio of 2.88 and a beta of 1.16.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company's revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Equities analysts predict that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be issued a $0.05 dividend. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker's dividend payout ratio (DPR) is 38.46%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on BRKR shares. Jefferies Financial Group set a $60.00 price objective on Bruker and gave the company a "buy" rating in a research note on Monday, August 4th. Barclays decreased their price objective on Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Monday, August 4th. Bank of America reduced their target price on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Citigroup lowered their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Finally, UBS Group dropped their price target on Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $51.30.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.